AI assistant
Sending…
LIGAND PHARMACEUTICALS INC — Director's Dealing 2021
Jan 6, 2021
31289_dirs_2021-01-05_75b97d62-7d8e-4fa4-b0ea-097d824767b3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2020-12-31
Reporting Person: HIGGINS JOHN L (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Common Stock | J | 223 | $84.5325 | Acquired | 235310 | Direct |
Footnotes
F1: Shares acquired under Ligand's employee stock purchase plan. Voluntary reporting exemption under Rule 16b-3(c).
More from LIGAND PHARMACEUTICALS INC
Proxy Solicitation & Information Statement
2026
May 18
Regulatory Filings
2026
May 18
Interim / Quarterly Report
2026
May 8
Regulatory Filings
2026
May 7
Major Shareholding Notification
2026
May 1
Major Shareholding Notification
2026
May 1
Regulatory Filings
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 27
Regulatory Filings
2026
Apr 27
Annual Report
2026
Apr 21